Blog
RSS FeedPosted by Michael Wonder on 13 Jan 2021
CADTH publishes initial recommendation for nivolumab for NSCLC
9 January 2021 - The pERC has conditionally recommended the reimbursement of nivolumab when used in combination with ipilimumab and ...
Posted by Michael Wonder on 13 Jan 2021
CADTH publishes initial pCODR recommendation for entrectinib
9 January 2021 - pERC has conditionally recommended the reimbursement of entrectinib for the first-line treatment of patients with ROS1 positive ...
Posted by Michael Wonder on 29 Oct 2020
CADTH publishes final recommendation for Blincyto
29 October 2020 - The pERC final recommendation is based on a reconsideration of the initial recommendation and feedback from eligible ...
Posted by Michael Wonder on 29 Oct 2020
Sales of cancer fighting drugs soared in Canada over the past decade
29 October 2020 - Canada is the only country with a universal health care system without coverage for prescription drugs. ...
Posted by Michael Wonder on 12 Oct 2020
Radiopharmaceutical cancer treatment Lutathera now available to Ontario patients with midgut neuroendocrine tumours
8 October 2020 - Lutathera is the first and only therapeutic radiopharmaceutical approved by Health Canada for the treatment of GEP-NETs. ...
Posted by Michael Wonder on 05 Oct 2020
Radiopharmaceutical Lutathera now reimbursed in Quebec for cancer patients with advanced gastro-enteropancreatic neuroendocrine tumours
1 October 2020 - Lutathera is the first and only therapeutic radiopharmaceutical indicated in the treatment of GEP-NETs in Canada. ...
Posted by Michael Wonder on 08 Sep 2020
Roche Canada announces FoundationOne Liquid CDx now available in Canada
8 September 2020 - Comprehensive pan-tumour liquid biopsy test analyzes >300 cancer-associated genes and multiple genomic signatures to inform treatment choices. ...
Posted by Michael Wonder on 13 Aug 2020
Impact of rarity on Canadian oncology health technology assessment and funding
11 August 2020 - The pan-Canadian Oncology Drug Review evaluates new cancer drugs for public funding recommendations. ...
Posted by Michael Wonder on 18 May 2020
Montreal mother launches desperate plea for help to access experimental cancer treatment
17 May 2020 - Montreal mother launches desperate plea to access experimental cancer treatment in U.S. amid COVID-19 travel restrictions. ...
Posted by Michael Wonder on 12 May 2020
Evaluation of the impact of patient involvement in health technology assessments: a scoping review
8 May 2020 - While involving patients in health technology assessment has become increasingly common and important around the world, little ...
Posted by Michael Wonder on 12 Nov 2019
'Incredibly upsetting': breast cancer patients dealing with shortage of common drug treatment
12 November 2019 - When Tricia Smith tried to fill her prescription for tamoxifen two weeks ago, she was shocked ...
Posted by Michael Wonder on 24 Oct 2019
Women living with metastatic breast cancer in British Columbia now have public access to Kisqali
23 October 2019 - Novartis Pharmaceuticals Canada is pleased to announce that British Columbia will now reimburse Kisqali (ribociclib) for eligible ...
Posted by Michael Wonder on 10 Oct 2019
Novartis completes certification of initial sites in Quebec for first approved Canadian CAR-T therapy, Kymriah (tisagenlecleucel)
9 October 2019 - Quebec government to reimburse Kymriah therapy for certain patients with life-threatening cancers who are in critical ...
Posted by Michael Wonder on 23 Sep 2019
Health‐related quality of life in oncology drug reimbursement submissions in Canada: a review of submissions to the pan‐Canadian Oncology Drug Review
23 September 2019 - In Canada, CADTH evaluates and makes recommendations for the reimbursement of cancer drugs. One component of ...
Posted by Michael Wonder on 20 Sep 2019
Addition of Kisqali to drug plan in Quebec expands access to treatment for metastatic breast cancer
19 September 2019 - Provincial reimbursement provides public access to treatment that may delay the progression of advanced breast cancer. ...